Our engagement in the political process is focused on the following areas: • Access to musculoskeletal care • Transparent, timely, and scientifically-based regulatory decision-making • Market-based payment or reimbursement • Strong protection of patents and other intellectual property rights • Open and competitive access to international markets • Tax policies that support innovation and global competitiveness • Sensible medical malpractice reform Specific policies of interest to Zimmer Biomet include the following: • Corporate Tax Policy – Zimmer Biomet supported the changes to the U.S. corporate tax code in 2017, which created a more globally competitive system for U.S. businesses by lowering the corporate tax rate and shifting to a territorial system. • Stability in Payment Policies – As innovation in medical technology changes the way that care is delivered, Zimmer Biomet supports payment and reimbursement policies that ensure stability and access for patients, providers, innovators and the entire healthcare ecosystem. • Diversity, Equity and Inclusion – Zimmer Biomet supports policies that strengthen a diverse and inclusive medical technology workforce and ensure equitable patient access to innovative devices and therapies. • Medical Device User Fee Amendments (MDUFA) – Zimmer Biomet supports a well-resourced and well- functioning U.S. Food and Drug Administration (FDA). The long-standing user fee program has helped FDA make significant improvements to the regulatory approval process for new medical devices. In 2021, Zimmer Biomet and its industry trade group began negotiations with FDA and Congress regarding changes to MDUFA in anticipation of legislation in 2022. • Support for International Trade Agreements – Zimmer Biomet supports trade policy initiatives that seek to improve access to medical devices in overseas export markets. How Zimmer Biomet Engages The primary means by which we engage in public policy debate is through communication of information to government officials, policy makers and their staffs. Zimmer Biomet’s Government Affairs office in Washington, D.C. is responsible for advocacy activities with the U.S. Congress and the Executive Branch, as well as advocacy at the state level. The Government Affairs office, which also has staff outside the United States, reports to the Senior Vice President and General Counsel. Globally, we currently have seven full-time employees wholly dedicated to Government Affairs matters. To assist with its advocacy and policy analysis work, Zimmer Biomet occasionally contracts with private firms specializing in government affairs advocacy. These firms provide the organization with expertise on issues that are important to Zimmer Biomet and our shareholders. In compliance with the U.S. Lobbying Disclosure Act , Zimmer Biomet files quarterly reports with the U.S. Congress describing our advocacy activities in Washington, D.C. and the amount of money spent each quarter to support these activities. These reports also include the cost of maintaining the Government Affairs office in Washington, D.C. and the portion of Zimmer Biomet’s trade association dues associated with advocacy activities. To view Zimmer Biomet’s quarterly lobbying expenditures, click on the above link and search for Zimmer Biomet under registrant. All Zimmer Biomet team members and agents must abide by our Code of Business Conduct and Ethics. This Code covers a wide range of business practices and procedures, and is designed to deter wrongdoing and promote the highest ethical standards. Among other things, the Code makes clear that no illegal payments of any kind (monetary or otherwise) are to be offered or made to an individual or entity—including officials or employees of national, state, local or foreign governments or national or foreign political candidates—at any time or under any circumstances. 24